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ARTICLE

OPEN

Identiﬁcation, validation, and targeting of the mutant p53PARP-MCM chromatin axis in triple negative breast cancer
Wei-Gang Qiu1,2,3, Alla Polotskaia1, Gu Xiao1, Lia Di1, Yuhan Zhao4, Wenwei Hu4, John Philip5, Ronald C. Hendrickson5 and
Jill Bargonetti1,6,7

Over 80% of triple negative breast cancers express mutant p53. Mutant p53 often gains oncogenic function suggesting that triple
negative breast cancers may be driven by p53 protein type. To determine the chromatin targets of this gain-of-function mutant p53
we used inducible knockdown of endogenous gain-of-function mtp53 in MDA-MB-468 cells in conjunction with stable isotope
labeling with amino acids in cell culture and subcellular fractionation. We sequenced over 70,000 total peptides for each
corresponding reciprocal data set and were able to identify 3010 unique cytoplasmic fraction proteins and 3403 unique chromatin
fraction proteins. The present proteomics experiment corroborated our previous experiment-based results that poly ADP-ribose
polymerase has a positive association with mutant p53 on the chromatin. Here, for the ﬁrst time we report that the
heterohexomeric minichromosome maintenance complex that participates in DNA replication initiation ranked as a high mutant
p53-chromatin associated pathway. Enrichment analysis identiﬁed the minichromosome maintenance members 2–7. To validate
this mutant p53- poly ADP-ribose polymerase-minichromosome maintenance functional axis, we experimentally depleted R273H
mutant p53 and found a large reduction of the amount of minichromosome maintenance complex proteins on the chromatin.
Furthermore a mutant p53-minichromosome maintenance 2 direct interaction was detected. Overexpressed mutant p53, but not
wild type p53, showed a protein-protein interaction with minichromosome maintenance 2 and minichromosome maintenance 4.
To target the mutant p53- poly ADP-ribose polymerase-minichromosome maintenance axis we treated cells with the poly
ADP-ribose polymerase inhibitor talazoparib and the alkylating agent temozolomide and detected synergistic activation of
apoptosis only in the presence of mutant p53. Furthermore when minichromosome maintenance 2–7 activity was inhibited the
synergistic activation of apoptosis was blocked. This mutant p53- poly ADP-ribose polymerase -minichromosome maintenance axis
may be useful for theranostics.
npj Breast Cancer (2017)3:1 ; doi:10.1038/s41523-016-0001-7

INTRODUCTION
Missense mutations in the TP53 gene often results in mutant p53
(mtp53) protein with gain-of-function (GOF) properties that are
associated with multiple types of cancers, including lung and
breast cancer.1 Mutations in p53 are found in 80% of triple
negative breast cancers (TNBC).2–4 A number of studies have been
carried out to elucidate the mtp53-associated breast cancer
transcriptome but the mtp53-targeted proteome is less well
studied.5–8 Mtp53 has not been found to interact with DNA sitespeciﬁcally but has been found to interact with cancer cell DNA in
association with other cofactors. Importantly mtp53 modiﬁes
chromatin structure to up-regulate vascular endothelial growth
factor receptor 29,10 and GOF mtp53 modiﬁes major chromatin
pathways by upregulating methyltransferase chromatin regulatory
genes MLL1, MLL2, and the acetyltransferase MOZ.11,12 While
changes in the transcriptome are a part of the mechanism of
action of GOF mtp53, there are also transcription-independent
mtp53 functions on chromatin that require further elucidation.

Very few studies have focused on the mtp53-associated
proteome but new work strongly indicates that alternative
experimental approaches are required to understand the complexity of the mtp53 pathway.7,13 A multiomics approach recently
identiﬁed the proteasome machinery as a common target of
missense mtp53.7 We are the only group to report on the
inﬂuence of endogenous GOF mtp53 on the spatial segregation of
the cancer cell proteome.6 The mtp53-associated cytosolic
proteome targets include up-regulation of cytoplasmic poly
ADP-ribose polymerase (PARP) when mtp53 is depleted6 and a
decrease in the cytosolic mavelonate pathway enzymes (which is
in agreement with previous transcriptome data).5 During validation of the spatially segregated proteins we discovered that downregulation of mtp53 caused a chromatin-segregated decrease of
PARP.6 We now report on the chromatin-segregated stable
isotope in cell culture (SILAC) screen to identify the spatially
restricted mtp53-targeted proteome of chromatin. We used a
bioinformatics approach to compare the cytoplasmic and
chromatin data sets (see Fig. 1 for the work ﬂow). Recent work
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Fig. 1 SILAC work ﬂow for proteomic targets. Four independent LC-MS/MS experiments were carried out to compare the proteomes of
chromatin and cytosolic proteomes with mtp53 knockdown. The work ﬂow diagram brieﬂy details the scientiﬁc steps from cell culture
conditions to the identiﬁcation of unique proteins. See Figs. 2 and 3 for identiﬁcation of chromatin pathway enrichment and the mutant p53
association index for speciﬁc proteins and pathways compared for chromatin and cytosolic fractions

suggests that a key regulatory role for mtp53 on chromatin is to
regulate transcription by chromatin remodeling,12 but we
hypothesized that DNA repair and DNA replication could also be
critical targets.
To our knowledge, there has been no direct evidence of GOF
mtp53 regulating chromatin-mediated DNA replication and repair.
Herein, we identiﬁed a mtp53-PARP-MCM chromatin axis by an
unbiased bioinformatics screen of spatially segregated cytoplasmic vs. chromatin SILAC data from R273H mtp53 knockdown in
TNBC cells. The enzyme PARP1 catalyzes the transfer of ADPribose to target proteins and plays a role in many cellular
processes including transcription, DNA replication, and DNA
repair.14,15 Herein, we validate the mtp53-PARP-MCM axis and
found that blocking PARP1 may be an excellent therapeutic target
for certain mtp53-expressing TNBCs.
RESULTS
Gain-of-function mtp53 inﬂuences 3403 chromatin proteins
Stable isotope labeling in cell culture (SILAC) of the MDA-MB-468.
shp53 cell line was carried out and mtp53 R273H was depleted by
inducible shRNA expression in two independent reciprocal
experiments. A work ﬂow diagram (Fig. 1) shows the experimental
approach that included cell fractionation and LC-MS/MS of heavy
and light extract mixed at a 1:1 protein concentration ratio. For
one experiment the mtp53 was depleted in the heavy label
conditions (13C6 L-Lysine-2HCl and 13C6 15N4 L-Arginine-HCl) and
for the other mtp53 was depleted in the light label conditions.
Chromatin fractionation was adapted from the Mendez and
Stillman protocol.6,16 Following gel electrophoresis we used liquid
chromatography and tandem mass spectrometry (LC-MS/MS) to
identify the mtp53 protein targets associated with the chromatin
fraction. We sequenced over 70,000 chromatin-associated
npj Breast Cancer (2017) 1

peptides and compared the heavy/light ratio resulting from the
depletion of mtp53 to determine how R273H knockdown
reciprocally inﬂuenced the 3403 representative proteins. The
chromatin mtp53 SILAC data were examined for gene set
enrichment and then compared to the cytosol mtp53 targets
determined in our previously published results.6 We carried out a
bioinformatics comparison of the inﬂuence of mtp53 depletion on
proteins in the cytosol to those affected on the chromatin.
Gene set enrichment analysis indicates that the hexomeric prereplicative MCM2–7 complex is the most highly enriched mtp53associated chromatin complex
The gene set enrichment analysis was performed using the GSEA
software (GSEA; version 2.0.14)17 to determine how chromatin
associated proteins were inﬂuenced by mtp53. A deﬁned set of
genes associated with the proteins that showed concordant
differences between the biological states of the mtp53 present, vs.
the mtp53 absent, was determined with pathways deﬁned by the
Reactome Pathway Database (version 4.0).18 The GSEA analysis of
the chromatin fraction revealed a total of 27 Reactome pathways
that were positively associated with mtp53 abundance at a
P value < 1%. Interestingly, a key pathway was the pre-replicative
complex, chromatin enriched proteome pathway, which is a novel
ﬁnding for mtp53 GOFassociations. The proteins in this pathway
are (in rank order): MCM2, MCM3, MCM6, ORC1, MCM4, MCM5,
MCM7, RPA2 and POLA2 (Fig. 2). The GSEA proteomic chromatin
enriched pathway sets are shown in their entirety at the link:
http://diverge.hunter.cuny.edu/~weigang/silac-chromatin-gsea/.
The ﬁrst three positive GSEA pathways in the list corresponded
with electron transport, which did not directly correlate with a
chromatin-associated pathway; we hypothesize this resulted from
insoluble cellular components that were associated with the
Published in partnership with the Breast Cancer Research Foundation
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Fig. 2 Knockdown of mtp53 identiﬁes enrichment of the pre-replicative complex pathway. GSEA analysis revealed a total of 27 and 17
Reactome pathways that are positively and negatively, respectively, associated with mtp53 abundance at a nominal P value < 1%. Enrichment
of ﬁve DNA replication-related gene sets and pathways including the pre-replicative complex consisting of 15 genes, shown here with their
enrichment scores (upper panel) and mutant p53 association index (mPAI) ranks (lower panel). Full GSEA results are available at http://diverge.
hunter.cuny.edu/~weigang/silac-chromatin-gsea/ (chromatin) and http://diverge.hunter.cuny.edu/Polotskaia_etal_2014/supp-table-s1/ (cytosol)

chromatin pellet. The fourth GSEA pathway associated with
generic transcription pathways, which are currently the focus of
many mtp53 GOF studies.12 However the ﬁfth pathway identiﬁed a
very speciﬁc chromatin associated pre-replicative pathway that has
not yet been studied for mtp53 involvement. The GSEA analysis
also demonstrated 17 Reactome pathways that were negatively
associated with mtp53 abundance at a P value < 1%. By clicking on
enrichment results in html format you will be directed to the
positive association protein sets and negative association protein
sets (Fig. 2). We are providing open access to this powerful data set.

mtp53 levels were high and redistributed to the cytosol when the
mtp53 was low as expected and the mPAI for PARP reﬂected this
as a negative value for the cytosol and a positive number for the
chromatin (Fig. 3). In support of our previous data, we determined
that PARP had a positive mPAI on the chromatin of 1.2 and a
negative mPAI in the cytosol of −2.3. Therefore in addition to
providing a new powerful data set we have identiﬁed a potentially
important mtp53 protein pathway that is involved in regulation of
DNA replication.

Distributions of mtp53 associated changes in the cytosol and on
the chromatin indicate that the hexomeric MCM2–7 complex
proteins reside in the double positive quadrant
The chromatin SILAC data were then compared to our previously
published cytosol set http://diverge.hunter.cuny.edu/Polotskaia_
etal_2014/supp-table-s1/. In order to further summarize and
quantify the degree of under- and over-expression of proteins
from the reciprocal knockdown experiments in the different subcellular fractions of the breast cancer cells we deﬁned a mtp53
association index (mPAI: see “Methods” for the statistical analysis).
Values of mPAI obtained from both the cytosol and chromatin
fractionations were normally distributed with a mean close to zero
and a standard deviation close to one, conforming to the
expectation that abundance of the majority of proteins were
indeed not impacted by mtp53 knockdown (Fig. 3). We thereby
identiﬁed proteins with mPAI > 1.0 as those displaying signiﬁcant
positive association with mtp53 abundance and those with
mPAI < −1.0 as showing signiﬁcant negative association with
mtp53 abundance. This was in agreement with the fact that
mtp53 knockdown did not inﬂuence the level of the majority of
the proteins in either the cytosol or chromatin sub-cellular
fractions. Moreover, in both sub-cellular fractions the standard
deviation of the mPAI was close to one and mtp53 itself showed
an mPAI value of greater than 2.0 (z-score > 2.0). The mtp53 mPAI
index was 3.0 on the chromatin, which was higher than the
positive 2.1 value identiﬁed in the cytosol. The mtp53 mPAI served
as excellent internal positive control as its levels necessarily were
reduced by shRNA mediated knockdown. Poly ADP ribose
polymerase (PARP) was associated with the chromatin when

Comparison of the nuclear and cytosol proteomes displays a
double positive mtp53 inﬂuence on the MCM 2-7 hexomeric
complex
The mPAI for the entire mtp53-inﬂuenced proteome in the cytosol
vs. the mtp53-inﬂuenced proteome on the chromatin were
graphed as coordinates of the chromatin proteome on the
Y-axis and the cytosol proteome on the X-axis. This resulted in a
scatter plot with four quadrants demonstrating differentially
inﬂuenced mtp53 associated proteins. Figure 4 shows a representative image with all the dots as grey shades, p53 as a prominent
red dot, the MCM2–7 helicase subunits as green dots (zoomed in in
upper right), and PARP as a blue dot. An interactive searchable
scatter plot is part of the Supplementary Data http://diverge.
hunter.cuny.edu/~weigang/mpai-browser/. Each dot represents a
protein and its mPAI in the cytosol and chromatin. The four p53inﬂuenced quadrants are (a) double positive in the top right, (b)
chromatin positive and cytosol negative in the top left, (c) double
negative in the bottom left, and (d) cytosol positive with
chromatin negative in the bottom right. The mtp53 protein is by
deﬁnition a double positive signal and it is highlighted as a red
dot (TP53, Fig. 4). The MCM2–7 pre-replication complex proteins
are shown in green and were all situated as double positives
(Fig. 4). The PARP1 protein appeared in the upper left quadrant
and is highlighted as a blue dot. PARP1 showed a negative
association with mtp53 in the cytosol and a positive association on
the chromatin, consistent with our previous experimental results.
The center of the scatter plot corresponds to proteins that are
unchanged by p53 knockdown. While the majority of proteins are
unchanged by the knockdown of mtp53 key proteins and

Published in partnership with the Breast Cancer Research Foundation
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Fig. 3 Distribution of mutant p53 association index (mPAI) scores in
the cytosol (top) and chromatin (bottom) fractionations. Histograms
of mPAI values (for equation see statistics in the methods) show
close ﬁt to normal curves (in dashed lines) obtained with the same
mean (µ = 0.0060 for cytosol, µ= 0.085 for chromatin) and standard
deviation (σ = 0.92 for cytosol, σ = 0.96 for chromatin). As expected
(and as a negative control of the experiments and the mPAI statistic),
most proteins are not signiﬁcantly impacted by mtp53 depletion,
showing −1 < mPAI < 1 (shaded in light gray). As a positive control,
the mTP53 protein level (in red) shows signiﬁcantly high positive
mPAI values. As another positive control, the PARP1 levels (in blue)
show contrasting mPAI values between the two fractionations,
consistent with previous experimental results.6 The six components
of the MCM2–7 complex (in green) show signiﬁcant positive
association with mtp53 in both cytosol and nucleus

pathways including those involved in DNA replication and repair
are strongly implicated.
Mutant p53 interacts with members of the MCM hexomeric
complex on chromatin
To verify that the R273H mtp53 levels inﬂuenced multiple MCM
hexomeric proteins on chromatin in different cells, we reduced
GOF mtp53 levels in MDA-MB-468 cells and HT-29 cells and used
Western blot analysis to examine MCM2, MCM4, and MCM7
(Fig. 5). When mtp53 was decreased the chromatin-associated
levels of MCM2, MCM4, and MCM7 were also decreased (Fig. 5a).
To further examine this interaction in situ and to determine if the
mtp53 was co-localized with the MCM2–7 we used proximity
ligation assay (PLA) with confocal microscopy detection.19 To our
knowledge we are the ﬁrst group to use antibodies in PLA to
detect the interaction of mtp53 and MCM2. Strong nuclear colocalization of mtp53 and MCM2 was apparent and this signal was
drastically reduced by the knockdown of mtp53 (Fig. 5b). The
results from the PLA documented an interaction between mtp53
and MCM2 that was restricted to the subcellular nuclear zone. Our
data showed that mtp53 R273H interacted with MCM2 in the
nucleus and made us interested in seeing if the interaction of
missense mtp53 with MCM2 was a more general phenomenon. In
order to address the interaction of other mtp53 isoforms and wildtype p53 with MCM2 we compared the MDA-MB-468 PLA signal to
those seen in a number of other cell lines (Supplemental Figure 1).
The confocal microscope settings were kept constant in order to
have a direct comparison. We observed a strong PLA signal
npj Breast Cancer (2017) 1

Fig. 4 A double-positive mtp53 association seen for all MCM2-7
complex proteins in cytosol (x-axis) and nucleus (y-axis). Each dot
(n = 1778) represents a protein with its position determined by its
mPAI values in the cytosolic (x-axis) and the chromatin fractionations
(y-axis). mPAI values were averaged if multiple peptides of the same
protein were identiﬁed. Two side boxplots show the median, the
lower and upper quartiles, and the range of mPAI values. The majority
of points fall inside the x = −1, x = 1, y = −1, and y = 1 lines,
indicating that abundance of most proteins are not signiﬁcantly
impacted by mtp53 knockdown in either fractionation. The mtp53
and the six members of the MCM2–7 complex fall in the top right
quadrant, where protein levels are positively associated with mtp53
levels in both fractionations. PARP1 falls in the top left quadrant
showing negative association with mtp53 in the cytosol but positive
association in the nucleus, consistent with our previous experiment
result.6 A searchable, zoomable, and clickable scatter plot of mPAI
values for 4798 genes and 1330 associated pathways and gene sets is
available at http://diverge.hunter.cuny.edu/~weigang/mpai-browser/

between R280K mtp53 and MCM2 in MDA-MB-231 cells and this
was reduced by mtp53 knockdown. We also observed a strong
PLA signal between R248Q mtp53 and MCM2 in HCC70 cells,
which again was reduced by mtp53 knockdown. Interestingly, we
detected some MCM2 interacting with the low level wtp53 in
MCF-7 cells and this reaction was stable. Therefore the high
concentration of different missense mtp53 on the chromatin in
cancer cells corresponds to a strong PLA signal with MCM2, and
even low-level wtp53 can be found in close proximity to MCM2. A
previously published immunoprecipitation screen of mtp53 R175H
found an interaction with MCM proteins that was reported only in
the Supplementary Data section.20 We found that exogenously
expressed mtp53 R175H, and to a much lesser extent wild-type
p53, interacted with both MCM2 and MCM4 (Fig. 5c). Mice with
the analogous human R175H knockin mutation (Trp53R172H/R172H)
develop lymphomas.21,22 We also found that the mtp53 in these
mouse tumors interacted with MCM4 (Fig. 5d). In mice with mtp53
R172H, the protein is low in normal tissue and is only found stable
and highly expressed in tumor tissue.23 Therefore it is not
surprising that there was very little mtp53 evident in the input, or
immunoprecipitation samples from normal tissue (Fig. 5, lanes 1,
2, 7, and 8). The fact that we observed a stronger interaction
between mtp53 R175H and MCM2, and a weaker interaction
between wtp53 and MCM2, corresponds with our observations for
comparative PLA analysis for multiple breast cancer cell lines
(Supplementary Figure 1). The MCM4 interaction in the coimmunoprecipitation was more difﬁcult to assess due to poor
antibody speciﬁcity, but nevertheless looked strongest for mtp53.
Published in partnership with the Breast Cancer Research Foundation
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Fig. 5 Mutant p53 associates with MCM2, MCM4 and MCM7 on chromatin. a Protein levels of MCM2, MCM4, MCM7, mtp53 and ﬁbrillarin in
the chromatin fraction were determined by Western blot analysis in MDA-468.shp53 cells grown in the presence or absence of 8 μg/ml of
doxycycline for 12 days, and HT-29 colon cancer cells transfected with p53-siRNA (p53) or control siRNA (Con). b Analysis of p53/MCM2
complexes (red) by immunoﬂuorescence microscopy in combination with in situ proximity ligation assay (PLA) in MDA-468 vector and MDA468.shp53 cells grown in the presence of 8 μg/ml of doxycycline for 12 days. DNA was counterstained with DAPI (blue) and GFP (green) was an
indicator of doxycyline-mediated induction. The z stack confocal maximum intensity projection images of p53/MCM2 and DAPI, p53/MCM2
and GFP are shown. c Co-immunoprecipitation (co-IP) of MCM2 and MCM4 with exogenously expressed mtp53 (R175H) and wtp53 in H1299
cells. Whole cell lystates of H1299 cells transfected with wtp53 or mtp53 were incubated with anti-p53 antibody followed by immunoblot with
anti-MCM2 or anti-MCM4 antibodies. d Co-IP of MCM4 and mtp53 in thymic lymphomas from mtp53 (Trp53R172H/R172H) mice. Thymic
lymphomas from mtp53 mice and p53−/− mice as well as normal thymic tissue from mtp53 mice were subjected to co-IP assays using antip53 antibody followed by immunoblot with anti-MCM4 antibody

From these data we conclude that all forms of p53 can be found in
close proximity to MCM proteins but that a higher level of
oncogenic mtp53 in cancer cells corresponds to a much more
robust signal for the proximity interaction with MCM proteins.
The fact that we do not see strong enrichment for coimmunoprecipitation of MCM proteins, but see a strong proximity
interaction suggests that the mtp53–MCM interaction is not due
to a strong direct protein–protein interaction.
Activation of apoptosis and PARP trapping is mitigated by
knockdown of mtp53 or inhibition of MCM2–7
We previously saw that the inhibition of PARP was more cytotoxic
in the presence of mtp53 than in its absence.6 We hypothesized
that this might be due to a mtp53–PARP–MCM interaction at
damaged DNA. Synergistic activity is seen when the PARP
inhibitor talazoparib is used in combination with the DNA
damaging agent temozolomide in BRCA1 mutant cells.24 It has
been shown that wtp53 expression decreases sensitivity of breast
cancer cells to PARP inhibition25 and ciproﬂoxacin blocks the
MCM2–7 complex.26 We asked if increased cytotoxity of PARP
inhibition could be detected in the presence of mtp53 if DNA was
damaged by alkylation. We predicted that there would be
synergistic activation of apoptosis of the breast cancer cell lines
with mtp53 in the presence of talazoparib plus temozolomide
because this alkylating agent has been shown to provoke PARP
trapping.27 We found that combination treatment with talazoparib
plus temozolomide induced synergistic activation of apoptosis
only in the presence of mtp53 and only when MCM2–7
processivity was not inhibited by ciproﬂoxacin (Fig. 6a–c). This
Published in partnership with the Breast Cancer Research Foundation

was detected by live cell confocal microscopy scoring for activated
caspases 3 and 7 (Fig. 6a–c). PARP inhibition by talazoparib plus
DNA damage with temozolomide resulted in synergistic cell killing
of MDA-MB-468 breast cancer cells that are wild-type BRCA1 and
R273H mtp53 (Fig. 6a; apoptotic cells are green stained with active
caspase 3 and 7). Moreover, when R273H mtp53 expression was
depleted by siRNA, or MCM2-7 was inhibited by ciproﬂoxacin this
synergistic activation was blocked (Fig. 6b and 6c). In addition, cell
viability reduced 59% in talazoparib plus temozolomide treatment
compared to non-treated cells (Fig. 6d). We also found, as
predicted, that combination treatment with talazoparib plus
temozolomide increased PARP trapping on the chromatin and
this was mitigated by the knockdown of mtp53 (Fig. 6e and 6f).
Moreover, depletion of mtp53 reduced the poly-ADP-ribosylated
(PAR) proteins in the combination treatment with talazoparib plus
temozolomide (Fig. 6e). Therefore mtp53 R273H and processive
MCM2–7 are required for the higher than additive killing seen
when cells are treated with talazoparib plus temozolomide.
DISCUSSION
High levels of mtp53 are found in over 50% of all human tumors
from patient samples.1 Somatic mutations in only three genes
occur at greater than 10% incidence across all different subtypes
of breast cancers, and one of these is mutation in the TP53 gene.2
More than 80% of TNBCs contain mtp53 protein.2–4 As far back as
1984 it was reported that the “oncogene” p53 cooperated with ras
to transform cells;28,29 however, we still do not use mtp53 as a
diagnostic or treatment-mediated paradigm. TNBCs may serve as
npj Breast Cancer (2017) 1
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Fig. 6 Activation of apoptosis and PARP trapping is mitigated by knockdown of mtp53 or inhibition of MCM2–7. Confocal maximum
projection of live-cell imaging in MDA-468 cells (a, c) or MDA-468 cells transfected with p53-siRNA or control siRNA (b) treated for 24 h with
temozolomide (Temo), talazoparib (Tal), combination (Temo + Tal) or ciproﬂoxacin (Cipro). Apoptotic cells (green) were detected by activated
caspase 3/7 green detection reagent and DNA was counterstained with DAPI (blue). Red ﬂuorescence was Propidium iodide staining. d MTT
assay shows reduction of mitochondrial activity after combination treatment of Temo plus Tal. e, f PARP trapping and PARylation with and
without mtp53 after 4 h treatment with Temo, Tal or combination (Temo + Tal). Protein levels of PARP, mtp53 and PARylated proteins in the
chromatin fraction were determined by Western blot analysis in MDA-468 vector and MDA-468.shp53 cells grown in the presence or absence
of 8 μg/ml of doxycycline for 12 days. The Western blot is a representative image. The histogram is based on signal intensity (quatiﬁed using
Image J software) from two independent experiments and normalized to untreated cells set as one. g Schematic model of the mtp53
dependent synthetic lethality by the combination of talazoparib plus temozolomide

an ideal paradigm for this approach. There are a number of highoccurrence “hot spot” mutations found in the TP53 gene that
result in amino acid substitutions that inhibit the site-speciﬁc DNA
binding activity of p53.8 Some TP53 mutations contribute to breast
cancer metastasis because of loss of p53 tumor suppressor
activity, many missense TP53 mutations cause new-found GOF
oncogenic activities that range from transcriptional activation of
target genes that promote tumorigenesis, to the inhibition of p53
family members p63 and p73.30 The GOF mtp53 proteins have a
prolonged half-life and are highly expressed in cancer cells.1,23
While mtp53-mediated regulation is known to occur in part by
activation and repression of gene transcription,8,30–32 mounting
evidence including data from our lab indicates that other
biochemical functions exist for mtp53.6,13,31 Improved detection
of proteomic signal transduction changes are observed with subcellular fractionation experiments of SILAC followed by LC-MS/
MS.33,34 We are the only group to study mtp53-proteome
interactions in the context of sub-cellular architecture, which is
critical for monitoring stability of proteins based on location. To
carefully analyze the proteomic data we designed an algorithm to
assay four data sets generated by inducible mtp53 knockdown in
conjunction with SILAC and mass spectrometry to rate the mtp53
association index (mPAI). The mPAI points were graphed in an
interactive four-quadrant map of proteomic changes to compare
cytosol and chromatin targets http://diverge.hunter.cuny.edu/
~weigang/mpai-browser/. The genes and pathways associated
with mtp53 were identiﬁed using GSEA and can be searched with
this interactive tool online. When MCM is typed in the gene search
npj Breast Cancer (2017) 1

tool you will see that all six members of the hexomeric complex
are found in the double positive quadrant. When the word
“replicative” is typed into the search pathway function the prereplicative pathway will appear and when the point is clicked all
six of the MCM proteins will show up again. The strength of this
online analysis tool is that, this is the ﬁrst time many other mPAI
pathways are presented and they are yet to be validated. Herein,
we validate the mtp53–PARP–MCM pathway. We identiﬁed that
mtp53 depletion also depleted chromatin-associated PARP and all
members of the MCM2-7 hexomeric complex. We are the ﬁrst to
show that mtp53 inﬂuenced MCM chromatin levels in multiple
cancer cell lines and directly associated with MCM2 in nuclei as
seen by confocal microscopy PLA (Fig. 5).
TNBCs are resistant to a number of different treatments;
temozolomide is one of the chemotherapeutic drugs TNBCs are
resistant to.35 It is clear that properties in addition to BRCA1/
2 status dictate the sensitivity to PARP inhibitors36 and we
hypothesize that mtp53 status (with speciﬁc hot spot mutations) is
a critical determinant. Synergistic activity is seen with the PARP
inhibitor talazoparib in combination with the DNA modiﬁer
temozolomide.24 PARP is recruited to DNA damage sites in
chromatin to block transcription and facilitate DNA repair34 and
recently MCM2-7 was also found to participate in DNA repair.37
Our study is the ﬁrst to directly show that the synergistic activity of
temozolomide plus talazoparib is dependent on the expression of
mtp53 and the processivity of MCM2–7 (Fig. 6). Interestingly the
proteomic study ﬁnding BAG2 stabilizes mtp53 also identiﬁed
MCM proteins interacting with mtp53, and the proteomic study
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ﬁnding MCM2–7 is involved in DNA repair also found BAG2
interacting with the complex.20,37 This suggests that stable mtp53
may help recruit MCM2–7 and PARP proteins to chromatin in
order to help cancer cells survive during replication stress. While
PARP inhibitors have been used to target breast cancers with
BRCA1 mutations,38 they have not been approved for use in
cancers that have mutation in the TP53 gene. Breast cancers with
BRCA1 mutations include many TNBCs, however PARP inhibitors
have not shown a direct correlation of effectiveness directly
related to BRCA1 and BRCA2 mutations in TNBCs.36 MDA-MB-468
cells and HCC70 cells do not have BRCA mutations and they are
more sensitive to PARP inhibitors than some breast cancer cell
lines that have BRCA mutations. Importantly both of these TNBC
cell lines express high levels of mtp53, however a correlation
between mtp53 status and PARP activity before now had not been
determined. Recent work has shown that the cytotoxicity of PARP
inhibitors requires that the inhibitors trap the PARP enzyme onto
the chromatin.27,39 Importantly, we found that in the presence of
mtp53, but not in its absence, combination treatment with the
PARP inhibitor talazoparib plus the DNA damaging agent
temozolomide resulted in efﬁcient PARP trapping and apoptosis
induction (Fig. 6).
It is of interest and important to determine if the temozolomide
plus talazoparib combination strategy works in vivo with a
speciﬁcity for tumor cells possessing speciﬁc p53 missense
mutations. We found that while mtp53 is highly associated with
MCM2 on the chromatin (Fig. 5b and Supplementary Figure 1A),
the mutation R273H associated with the highest level of
synergistic killing by the combination treatment, and the
sensitivity for cells with other p53 missense mutations varied
(Supplementary Figure 1B). There have been demonstrations of
remarkably synergistic activity of the PARP inhibition by talazoparib plus temozolomide in a subset of pediatric Ewing Sarcoma
xenografts.24 The genomic landscape of Ewing Sarcoma shows an
aggressive subtype with TP53 mutations.40 The p53 status has
been reported for many of the cell lines used for the Ewing
Sarcoma xenograft models, and there is not a direct correlation
between the p53 mutation status and those cell lines that are
sensitive to combination treatment vs. those that are not.24 Cancer
cell sensitivity to combination treatment may be speciﬁc for
certain p53 missense mutations in collaboration with other driver
or passenger mutations. We previously documented that the
depletion of mtp53 in MDA-MB-231 cells does not reduce MCM
protein on the chromatin.6 Herein, we saw that there was an
interaction between mt53 R280K and MCM2 in MDA-MB-231 cells;
however combination temozolomide plus talazoparib treatment
of MDA-MB-231 cells did not cause synergistic killing (Supplementary Figure 1B). It is possible that missense mtp53, in different
contexts, inﬂuences PARP and MCM in different ways. Experiments
are needed to elucidate the relationship between different p53
missense mutants, and accessory proteins, for inﬂuencing PARP
and MCM2-7 structure and function.
Homologous-recombination-deﬁcient tumors are dependent on
DNA-replication repair mechanisms that are more sensitive to
PARP inhibitors.41 It is possible the certain missense mutants of
p53 block homologous-recombination in humans, as the p53 in
C. elegans inhibits nonhomologous end joining while promoting
high ﬁdelity homologous recombination.42 Our results describe
the close proximity between mtp53 and the replication initiator
mini chromosome maintenance complex MCM2-7 on replicating
DNA. However, they suggest that each missense mutation has to
be evaluated for its speciﬁc activity. Researchers have found a way
to reactivate mtp53 to become wild-type like, but this reactivation
is allele speciﬁc for R175H.43,44 The ability to target a characteristic
of multiple mtp53 proteins will enable using the newfound mtp53
activities to be used against tumorigenesis. Our results implicate
an interaction of stable mtp53 at replication forks, and with PARP
on the chromatin that can be used to sensitize cancer cells to die.
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We saw that the processivity of the MCM2-7 complex was required
for synergistic mtp53-dependent induction of apoptosis by the
combination of talazoparib plus temozolomide (see model in
Fig. 6g). The MCM2–7 multi-subunit helicase participates in driving
DNA replication and improves replication under stressful conditions. This may be the connection between mtp53 and MCM2–7
facilitating the synthetic lethal function of PARP inhibition in
treating TNBC. The disruption of p53 by mutation often allows the
subverted protein to interact with normal partners of wild-type
p53 but differentially inﬂuences the outcome.45 It remains to be
determined if PARP and MCM2–7 will be added to the list of
proteins that are inﬂuenced by wild-type and mtp53 in opposing
ways or if this is a new paradigm. Our ﬁndings demonstrate a
connection between mtp53 expression in TNBC and the ability to
target cells with the combination therapeutic drug protocol
previously intended for BRCA1 mutated cancers. Taken together,
our ﬁndings suggest that certain mtp53 missense mutations drive
PARP trapping and then MCM2–7 helps to facilitate the increased
cytotoxicity of PARP inhibitors plus temozolamide. This data also
suggests that the treatment of TNBC, with speciﬁc mtp53 proteins,
by PARP inhibitors plus temozolamide may have promising
therapeutic effects and therefore the use of mtp53 status in
TNBC may be a predictive marker for combination PARP-trapping
therapy response.
METHODS
Statistical analysis
We quantiﬁed the degree of under- and over-expression of proteins from
the reciprocal knockdown experiments in the different sub-cellular
fractions of the breast cancer cells by deﬁning a mPAI. The mPAI was
deﬁned as
"  #
" 
#
H
H
mPAI ¼ log2
 log2
;
L exp1
L exp 2
 
where HL exp 1 is the ratio of peptide abundance in an experiment in
which the control cells were labeled with the heavy isotope and
  the mtp53
knockdown cells were labeled with the light isotope, and HL exp 2 is the
corresponding ratio in the reciprocally labeled experiment. The use
of logarithm with base two converts these ratios to the unit of fold
changes between the control and the knockdown cells. When abundance
of a protein is not affected by mtp53 knockdown, both H/L ratios are
expected to be close to one, resulting in an mPAI ~ 0. For a protein with
abundance increased by the presence of mtp53, ðHLÞexp 1 is expected to
 
be >1 and HL exp 2 < 1, resulting in an mPAI > 0. Conversely, mPAI was
expected to be <0 for a protein with abundance decreased by the
presence of mtp53.
Reagents. Doxycyclin, aprotinin, leupeptin, DTT, temozolomide and
ciproﬂoxacin were obtained from Sigma, Talazoparib BMN 673 from
Selleckchem.
CellEvent Caspase-3/7 Green and ReadyProbes Cell Viability Imaging Kit
Blue/Red for Live Cell Imaging were obtained from Life Technologies.
Duolink in situ red kit goat/rabbit (Sigma) was used for PLA assay.
Cell lines. MDA-MB-468, H1299 and HT-29 cell lines were obtained from
ATCC and cultured in DMEM or McCoy’s (for HT-29) medium (Invitrogen),
supplemented with 10% FBS (Gemini, West Sacramento, CA, USA) and 50
U/ml penicillin and 50 µg/ml streptomycin (Mediatech). Cell lines with the
inducible p53 knockdown were generated and described previously.5,46,47
To induce shRNA expression cells were treated with 8 µg/ml of doxycyclin
(Dox) for the time periods indicated in the ﬁgure legends, fresh medium
with Dox was supplemented every 48 h.
Antibodies. Anti-human p53 mouse 1:1:1 mix of hybridoma supernatants
pAb421, pAb240, and pAb1801 (N-terminus, Central and C-terminus
regions respectively), rabbit anti-Actin (Sigma); mouse anti-Fibrillarin
(AbCam), mouse anti-PARP-1 (Santa Cruz), rabbit anti-PAR (Millipore/
npj Breast Cancer (2017) 1
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Calbiochem), anti-MCM2, MCM4, MCM7 (Cell Signaling), secondary antibody: anti-mouse and anti-rabbit HRP-conjugated (Sigma).
Sub-cellular fractionation. Cells were harvested and fractionation was
performed using the Stillman protocol.16 Brieﬂy, cells were scraped from
the plates, rinsed with cold PBS twice and pelleted by centrifugation in
50 ml tubes at 1000 rpm 5 min. Cell pellets were resuspended in buffer A
(10 mM HEPES pH 7.9, 10 mM KCl, 1.5 mM MgCl2, 0.34 M sucrose, 10%
glycerol, 1 mM DTT, 0.5 mM PMSF, 2 µg/ml leupeptin, 8.5 µg/ml aprotinin)
with 0.1% Triton X-100. After 5 min incubation on ice cells were transferred
to Eppendorf tubes and spun down at 3600 rpm for 5 min at 4 °C. The
supernatant was spun down for an additional 5 min at 13,000 rpm at 4 °C
to clarify (Cytoplasmic Fraction). Pellets were washed two times with Buffer
A by centrifugation at 3600 rpm for 5 min at 4 °C. The nuclear pellet was
resuspended in Buffer B (3 mM EDTA, 0.2 mM EGTA, 0.5 mM PMSF, 2 µg/ml
leupeptin, 8.5 µg/ml aprotinin) and incubated on ice 30 min with vigorous
vortexing every 5 min and spun down at 4000 rpm for 5 min at 4 °C. The
supernatant was nuclear soluble proteins. The pellet enriched in
chromatin, was washed two times with Buffer B, resuspended in buffer B
and sonicated three times for 30 s followed by 30 s rest on ice (Chromatin
Fraction). Samples were stored at −80 °C.
Gel electrophoresis and immunoblotting. Proteins were separated using
10% SDS-PAGE and transferred to a nitrocellulose membrane. The
membrane was blocked in 5% non-fat milk solution in PBS/0.1%
Tween 20 and probed overnight at 4 °C. Washes were done with PBS/
0.1% Tween 20 solution. Secondary anti-mouse or anti-rabbit antibody
(Sigma) was applied to the membrane for 1 h at room temperature and the
membrane was washed three times. Protein signal was visualized by
chemiluminescence using the Super Signal West Pico Kit (Pierce) and
detected after exposure for autoradiography to Hyblot CL ﬁlms (Denville
Scientiﬁc).

Quantitative proteomics by stable isotope labeling in cell culture
SILAC mass spectrometry
For SILAC mass spectrometry, we used Protein Quantitation Kit—DMEM
(Pierce) with 13C6 L-Lysine-2HCl and added to the media a second amino
acid 13C6 15N4 L-Arginine-HCl (Pierce) for double labeling. Cells were
passaged for at least ﬁve cell doublings by splitting cells when required
and isotope incorporation efﬁciency was determined by MS analysis. MDA468.shp53 R273H depleted and non-depleted cells were cultured in media
containing either non-labeled or labeled amino acids, harvested,
fractionated, cytoplasmic, or chromatin fractions were mixed at 1:1 ratio,
separated by SDS-polyacrylamide gel electrophoresis, stained with
GelCode Blue Stain Reagent (Thermo Scientiﬁc), and 15 gel sections
excised with in situ trypsin digestion of polypeptides in each gel slice
performed as described.48 The tryptic peptides were desalted using a 2 µl
bed volume of Poros 50 R2 (Applied Biosystems, CA) reversed-phase beads
packed in Eppendorf gel-loading tips.49 The puriﬁed peptides were diluted
to 0.1% formic acid and each gel section was analyzed separately by
microcapillary liquid chromatography with tandem mass spectrometry
using the NanoAcquity (Waters) with a 100-μm-inner-diameter × 10-cmlength C18 column (1.7 um BEH130, Waters) conﬁgured with a 180-µm ×
2-cm trap column coupled to a Q-Exactive mass spectrometer (Thermo
Fisher Scientiﬁc). Key parameters for the mass spectrometer were: AGC 3
E6, resolution 70,000. Tandem mass spectrometry fragmentation spectra
were searched for protein identiﬁcation using the Andromeda search
engine (http://maxquant.org/) against the reversed and concatenated
IPI_HUMAN protein database (v3.87). One unique peptide was required for
high-conﬁdence protein identiﬁcations and a minimum ratio count of two
peptides (one unique and one razor) were required for SILAC ratio
determination. Normalized SILAC ratios (H/L) were used for subsequent
analysis. All MS/MS samples were analyzed using MaxQuant (Max Planck
Institute of Biochemistry, Martinsried, Germany; version 1.3.0.3) at default
settings with a few modiﬁcations. The default was used for ﬁrst search
tolerance and main search tolerance: 20 and 6 ppm, respectively. Labels
were set to Arg10 and Lys6. MaxQuant was set up to search the reference
human proteome database downloaded from Uniprot on April 2, 2013.
Maxquant performed the search assuming trypsin digestion with up to two
missed cleavages. Peptide, Site, and Protein FDR were all set to 1% with a
minimum of 1 peptide needed for identiﬁcation but two peptides needed
to calculate a protein level ratio. The following modiﬁcations were used
as variable modiﬁcations for identiﬁcations and included for protein
quantiﬁcation: Oxidation of methionine, acetylation of the protein
npj Breast Cancer (2017) 1

N-terminus, phosphorylation of serine, threonine and tyrosine residues,
and propionamide for acrylamide adducts on cysteine. Raw data ﬁles are
publicly available via the Chorus data repository (https://chorusproject.org)
with project I.D. number 1266. Original MaxQuant result ﬁles can be
provided upon request.
RNA interference and transfection. For siRNA experiments, HT-29 cells
were seeded at 60% conﬂuence in media without penicillin—streptomycin
and allowed to attach overnight. Cells were transfected with 100 nM of p53
or non-targeted siRNA smart pool from Dharmacon for 6 h using
Lipofectamine 2000 (Invitrogen) as per manufacturers protocol. At the
end of the incubation period equal volume of McCoy’s media with 40%
FBS was added, next morning fresh media with 10% FBS was added
and the cells were allowed to grow for 72 h. Cells were harvested by
scraping into the media, washed with PBS and lysed for chromatin
fractionation.

Live cell imaging
Cells were seeded at 2 × 105 per well in a 12-well glass bottom plate
(MatTek, Ashland, MA, USA). Detection of apoptotic cells was performed
using the CellEvent™ Caspase 3/7 Green Detection Reagent (Life
Technologies). After treatment, cells were stained with 50 µl CellEvent
Caspase-3/7 green ready probes reagent and 50 µl ReadyProbes Cell
Viability Imaging Kit Blue/Red (Life Technologies) for 15 min at room temp.
z-stack images of stained cells were taken by confocal microscopy using a
Nikon A1 confocal microscope with 20x objective. Active caspase-3/7:
green ﬂuorescence, Propidium iodide: red ﬂuorescence, Nuclear DNA: blue
ﬂuorescence.

In situ PLA
Cells were seeded at 2 × 105 per well in a 12-well glass bottom plate
(MatTek). After removing the media, cells were rinsed with cold PBS three
times, ﬁxed in 4% formaldehyde for 15 min and permeabilized in 0.5%
Triton x-100 in PBS for 10 min at room temperature. After washing three
times in PBS and one time in distilled water for 2 min, cells were then
carried out PLA assay using Duolink in situ red kit goat/rabbit (SigmaAldrich) according to the manufacturer’s instructions. Brieﬂy, cells were
incubated in the blocking buffer for 30 min at 37 °C in a humidiﬁed
chamber and then incubated with primary antibodies diluted in the
antibody diluents overnight at room temperature in a humidiﬁed chamber.
On the following day, cells were washed in Buffer A for 5 min three times
and incubated with the PLA probes (anti-rabbit minus and anti-Goat plus)
for 60 min at 37 °C in a humid chamber. This was followed by 5 min wash
in Buffer A for two times. The ligation reaction was carried out at 37 °C for
60 min in a humid chamber followed by two times 2 min wash in Buffer A.
Cells were then incubated with the ampliﬁcation mix for 100 min at 37 °C
in a darkened humidiﬁed chamber. After washing with 1× Buffer B for
10 min for two times and a 1 min wash with 0.01× buffer B, cells were
mounted with mounting media containing with 4′,6-diamidino-2-phenylindole (DAPI). z-stack images were taken using Nikon A1 confocal
microscope with 60× objective oil immersion. The acquisition software is
Nikon elements. The primary antibodies were rabbit anti-p53 (Cat# A300247A) and goat anti-MCM2 (Cat# A300-122A) from Bethyl Laboratories.

Immunoprecipitation (IP) assays
IP assays were performed as previously described50 to determine mtp53
binding proteins in human cancer cells and mouse tumor tissues. In brief,
1 × 106 p53 null H1299 cells were transfected with expression vectors of
wtp53 or mutp53 (R175H). Cells were collected and lysed in NP-40 buffer
24 h after transfection for IP experiments by using anti-p53 antibody
(DO-1) (Santa Cruz) to pull down mtp53 and its binding proteins. For
tissues of normal and thymic lymphomas from mtp53 knock-in mice
(Trp53R172H/R172H) as well as thymic lymphomas from p53 knockout
mice, 1 mg tissue lystates in NP-40 buffer were used for IP using anti-p53
antibody (FL393) (Santa Cruz).
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